FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
1.395
+0.015 (1.09%)
Apr 6, 2026, 3:05 PM EDT - Market open
FibroBiologics Employees
FibroBiologics had 15 employees as of December 31, 2025. The number of employees increased by 2 or 15.38% compared to the previous year.
Employees
15
Change (1Y)
2
Growth (1Y)
15.38%
Revenue / Employee
n/a
Profits / Employee
-$1,243,067
Market Cap
6.34M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 2 | 15.38% |
| Dec 31, 2024 | 13 | 3 | 30.00% |
| Dec 31, 2023 | 10 | 3 | 42.86% |
| Sep 30, 2023 | 8 | 1 | 14.29% |
| Jun 30, 2023 | 7 | - | - |
| Dec 31, 2022 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| KALA BIO | 38 |
| Aptevo Therapeutics | 37 |
| AIM ImmunoTech | 23 |
| VivoSim Labs | 14 |
| Revelation Biosciences | 9 |
| Akari Therapeutics, | 9 |
| Dermata Therapeutics | 8 |
| Silo Pharma | 3 |
FBLG News
- 3 days ago - FibroBiologics Announces Closing of $3 Million Public Offering - GlobeNewsWire
- 5 days ago - FibroBiologics Announces Pricing of $3 Million Public Offering - GlobeNewsWire
- 5 days ago - FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial - GlobeNewsWire
- 11 days ago - FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement - GlobeNewsWire
- 25 days ago - FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology - GlobeNewsWire
- 4 weeks ago - FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - GlobeNewsWire
- 5 weeks ago - FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis - GlobeNewsWire
- 5 weeks ago - FibroBiologics to Present at the BIO Investment & Growth Summit - GlobeNewsWire